Physician profile
Daniel Forman
NPI 1780633941
$57,879.67
in general payments reported to CMS, 2019-2025
20 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $12K · 2021: $8,097 · 2022: $16K · 2023: $135 · 2024: $194 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37,966.99 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $12,271.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $6,144.57 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $318.52 | 2021 | |
| Pharmacosmos Therapeutics INC. | $153.15 | 2025 | Cosela, Monoferric |
| Novartis Pharmaceuticals Corporation | $150.39 | 2023-2025 | |
| Btg International INC. | $148.08 | 2020 | |
| Sobi, INC | $144.91 | 2024-2025 | |
| Novo Nordisk INC | $123.99 | 2022 | |
| Janssen Biotech, INC. | $104.63 | 2023-2025 | Rybrevant, Tecvayli, Erleada |
| Alexion Pharmaceuticals, INC. | $88.72 | 2023-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $74.96 | 2024 | Krazati |
| Beone Medicines USA, INC. | $32.33 | 2025 | Tevimbra, Brukinsa |
| Pfizer INC. | $27.43 | 2023 | |
| Adc Therapeutics America, INC. | $25.50 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $23.80 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $23.80 | 2025 | Verzenio, Inluriyo, Jaypirca |
| Abbvie INC. | $20.73 | 2025 | |
| Incyte Corporation | $18.95 | 2025 | Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $17.18 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.